Безопасность терапии адалимумабом

1. <div><p>Насонов Е.Л. Перспективы применения полностью человеческих моноклональных антител к фактору некроза опухоли (адалимумаб) при ревматоидном артрите. Клин, фармакол. терапия, 2007, 1, 71-74.</p><p>Алекберова З.С. Адалимумаб в терапии ревматоидного артрита. Научно-практ. ревматология, 2007, 4, 103-108.</p><p>Braun J., Sieper J., Dreban M. et at. Anti-tumour necrosis factor a therapy for ankylosing spondylitis: international experience. Ann.Rheum.Dis., 2002, 61, suppl.Ill, 51-60.</p><p>Kavanaugh A, TutuncuZ, Catalan-Sanchez T. Update on anti-tumor necrosis factor therapy in the spondyloarthropathy including psoriatic arthritis. Curr Opin Rheumatol., 2006, 18, 347-353.</p><p>Kempeni J. Preliminary results of early clinical trials with the fully human anti -TNFa monoclonal antibody D2E7.Ann.Rheum.Dis., 1999, 58, suppl. 1. 170-172.</p><p>Van de Putte L.B.A., Atkins C., Valaise M. et al. Efficacy and safety of adalimumab in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum.Dis., 2004, 63, 508-516.</p><p>Bennett A. N., Peterson P., Zain A. et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology, 2005, 44, 1026-1031.</p><p>Furst D.E., Schiff M.H., Fleischmann R.M. et al. Adalimumab, a fully human anti-TNF-a monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis. J.Rheumatol., 2003, 30, 2563-2571.</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. Arthr.Rheum., 2003, 48, 35-45.</p><p>Weinblatt M.E., Keystone E.C., Furst D.E. et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA year extended study. Ann.Rheum.Dis., 2006, 65, 753-759.</p><p>Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al. The PREMIER Study. A multicenter, randomized, double-blind clinical study of combination therapy with adalimumab and methotrexate versus methotrexate alone or adalimumab alone in patients with early,aggressive rheumatoid arthritis who had not had pre­vious methotrexate therapy. Arthr.Rheum., 2006, 54, 26-37.</p><p>Navarro-Sarabia F, Ariza-Ariza R, Hemandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. J. Rheumatol., 2006; 33, 1075-1081.</p><p>Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumour necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo- controlled, 52 weeks trial. Anhr.Rheum., 2004, 50, 1400-1411.</p><p>Schijf MH, Burmester GR, Kent JD, et al. Safety analysis of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum.Dis., 2006, 65, 889-894.</p><p>Burmester G.R., Mease P.J., Dijkmans B.A. et al. Adalimumab safety profde in global clinical trials and reduction in standardized mortality ratios (SMR) across multiple indications. Arthr.Rheum., 2007, 56, suppl., S399.</p><p>Lipsky P., Heijde van der D., St Clair E. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl. J. Med., 2000, 343, 1594-1602.</p><p>Anderson P.J. Tumor necrosis factor inhibitors: clinical implications of their immunogenicity profiles. Semin. Arthr.Rheum., 2005, 34, suppl.I, 19-22.</p><p>Opris D., Balanescu A., Bojinca A. et al. Tuberculosis in patients with rheumatoid arthritis treated with biologic agents. Ann.Rheum.Dis., 2006, 65, suppl.II, 496.</p><p>Akkoc N., San I., Akar S. et al. Tuberculosis in patients on anti-TNF therapy in Turkey. Ann. Rheum. Dis., 2006, 65, suppl.II, 499-500.</p><p>Tsiodras S., Samonis G., Boumpas D. Т., Kontoyiannis D. P. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin.Proc., 2008, 83, 181-94.</p><p>Dixon W.G., Symmons D.P.M., Lunt M. Serious infection following anti-tumor necrosis factor a therapy in patients with rheumatoid arthritis. Arthr. Rheum., 2007, 56, 2896-2904.</p><p>Nikas S.N., Voulgari P. V, Alamanos Y. et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann.Rheum. Dis., 2006, 65, 257-260.</p></div><br />